IONS catalysts
Catalysts and events linked to IONS, newest first.
IONS stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy Therapies 2026-09-24 · Up | pipeline commercialization potential via partnered Phase III successes | Ionis announces positive Phase III data for ulefnersen (FUS-ALS) and sefaxersen (IgAN). | Not recorded |
| Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease 2026-09-24 · Up | biotech pipeline derisking and anticipated regulatory milestone payments | Positive Phase III FUSION and IMAgINATION study outcomes for ulefnersen and sefaxersen. | Not recorded |
| Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs 2026-09-24 · Up | biotech pipeline derisking and future commercial royalty realization | Positive Phase III FUSION and IMAgINATION data met primary endpoints. | Not recorded |
| Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease 2026-09-24 · Up | pipeline de-risking and commercialization milestone realization | Ionis announced positive phase III results for two partnered programs: ulefnersen in FUS-ALS and sefaxersen in IgAN. | Not recorded |
| Ionis slides over 40% year-to-date following late-stage clinical setbacks 2026-09-21 · Mixed | biotech pipeline valuation compression on phase 3 clinical execution risk | Stock dropped >40% YTD on pelacarsen and eplontersen trial setbacks | Not recorded |
| Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks 2026-09-21 · Down | clinical pipeline NPV write-down and milestone cash flow contraction | Stock dropped over 40% year-to-date on pelacarsen and eplontersen pipeline failures. | Not recorded |
| Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacks 2026-09-21 · Down | clinical pipeline delay and milestone revenue deferral | Ionis shares dropped over 40% YTD following pelacarsen and eplontersen trial setbacks. | Not recorded |
| Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and Eplontersen 2026-09-21 · Down | milestone and commercial royalty impairment on clinical failures | Source confirms stock dropped >40% YTD following late-stage clinical trial failures in pelacarsen and eplontersen. | Not recorded |
Do these developments change your position?
Review IONS alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney DiseaseAZN IONS+1.57%
- 2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney DiseaseAZN IONS+1.57%
- 2026-09-24Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney diseaseIONS+1.57%
- 2026-09-24Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy TherapiesIONS+1.57%
- 2026-09-24Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney diseaseIONS+1.57%
- 2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney DiseaseAZN IONS+1.57%
- 2026-09-24Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy TherapiesIONS+1.57%
- 2026-09-24Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN ProgramsIONS+1.57%
- 2026-09-21Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacksIONS+1.49%
- 2026-09-21Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacksIONS+1.49%
- 2026-09-21Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish TargetsIONS+1.49%
- 2026-09-21Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and EplontersenIONS+1.49%
- 2026-09-21Ionis slides over 40% year-to-date following late-stage clinical setbacksAZN IONS+1.49%
- 2026-09-21Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacksAZN BIIB IONS+1.49%
- 2026-09-21Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacksAZN IONS+1.49%
- 2026-09-21Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and EplontersenAZN BIIB IONS+1.49%
- 2026-09-21Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish TargetsAZN IONS+1.49%
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointIONS NVS-11.45%
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointIONS NVS RPRX-11.45%
- 2026-08-26Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 FirmsIONS TEVA XBI-2.50%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.